论文部分内容阅读
研究了抗心律失常新药bidisomide,α-{2-[乙酰(1-甲乙基)氨基]乙基}-α-(2-氯苯基)-1-六氢吡啶仲丁酰胺对犬实验性心律失常的影响以及对离体窦房结标本和乳头肌标本的影响。实验结果表明,bidisomide能够有效地对抗氟烷-肾上腺素所诱发的心律失常、洋地黄所诱发的心律失常以及冠状动脉二步结扎法所诱发的犬实验性室性心律失常(P<0.05或P<0.01)。本文还通过测定不同时间的血药浓度,计算了能使心律失常的比值(单位时间内异位室性节律占总心跳次数的百分比)降低50％时的血药浓度IC_(50)。其结果,bidisomide抑制氟烷-肾上腺素性心律失常和洋地黄性心律失常的IC_K(50)分别为58.7μg/ml和22.1μg/ml;在冠状动脉二步结扎法
A novel antiarrhythmic drug bidisomide, alpha-{2-[acetyl(1-methylethyl)amino]ethyl}-α-(2-chlorophenyl)-1-hexahydropyridine sec-butyramide, was used to study the experimental rhythm of dogs. Effects of disorders and effects on isolated sinus node specimens and papillary muscle specimens. The experimental results show that bidisomide is effective against halothane-adrenergic-induced arrhythmias, digitalis-induced arrhythmias, and canine experimental ventricular arrhythmias induced by coronary artery two-step ligation (P<0.05 or P). <0.01). In this paper, the plasma concentration IC 50 of the arrhythmia ratio (percentage of ectopic rhythm per unit time in the total heart rate per unit of time) decreased by 50% was calculated by measuring blood concentration at different times. As a result, IC50 (50) for bidisomide inhibition of halothane-adrenergic arrhythmias and digitalis arrhythmias was 58.7 μg/ml and 22.1 μg/ml, respectively;